CompletedNCT00199966
Divalproex extended release for bipolarity in children and adolescents
About this title
Safety And Efficacy Study Of Depakote ER To Treat Pediatric Bipolar Disorder
Read the official source — NCT00199966Medication studyAges 6–17United States
Understand this study
Who was this study for?
Listed age limits: 6 years to 17 years.
- Listed locations
- MilwaukeeSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2003
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- Medical College of Wisconsin
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT00199966
- Official title
Show the full official title
A Pilot Study Of Safety And Effectiveness For Depakote ER In Pediatric Bipolar Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Milwaukee
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Medical College of Wisconsin, a university.
Did this study involve medication?
Yes. The study involved medication, including Divalproex sodium extended release.
Who was this study for?
Listed age limits: 6 years to 17 years.
